SARS-CoV-2 causes persistent infections in a subset of individuals, which is a major clinical
and public health problem that should be prioritised for further investigation for several …

Background Immunocompromised patients with impaired humoral immunity are at risk for
persistent COVID-19 (pCOVID), a protracted symptomatic disease with active viral …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …

COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …

Objectives After the third year of the COVID-19 pandemic, most of the severe COVID-19
burden falls upon immunocompromised patients who cannot mount an endogenous …

Plasma collected from people recovered from COVID-19 (COVID-19 convalescent plasma,
CCP) was the first antibody-based therapy employed to fight the pandemic. CCP was …

The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due
to its high transmissibility, although it appears to be less pathogenic than previous strains …

We present a retrospective study on the treatment outcomes of severely
immunocompromised patients with persistent COVID-19. The study analyzed data from 14 …

Background Patients with hematological malignancies (HM) were at a high risk of
develo** severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess …